Such efforts are paramount in order to advance the current DKD treatment paradigm, which largely remains unchanged since the discovery of angiotensin receptor inhibition in the 1990s and consists of glycemic control, blood pressure management, fluid balance, and angiotensin-converting enzyme (ACE) inhibition [71,72,73,74,75,76,77]. This evidence concerns the gene ACE and diabetic kidney disease.